Clinical trial NCT06541652: A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
Official title: A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Hepatocholangiocarcinoma
Fibrolamellar Carcinoma
Hepatic Epithelioid Hemangioendothelioma
Hepatoblastoma
Hepatic Neuroendocrine Carcinoma
Hepatic Carcinosarcomas
Hepatic Cystadenoma
Hepatic Leiomyosarcomas
Hepatic Angiosarcomas
Cholangiocarcinoma
Keywords: rare primary liver cancers
LIVER
HEPATIC
COHORT
RISK FACTORS
Lead sponsor: Federation Francophone de Cancerologie Digestive
Sponsor class: OTHER
Collaborators: name: Société Nationale Française de Gastroentérologie
First posted: 2024-08-07
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: In the health centers, patients were identified in two ways:

1. via diagnoses obtained in the anatomopathology departments of each investigating center
2. via multidisciplinary consultation meetings on primary hepatic tumours/digestive oncology at each investigating center.

Patients with a diagnosis of rare primary hepatic cancers diagnosed on or after 01/01/2018 may be included, whether alive or deceased at the time of registration in the CAPRIH cohort.

Brief summary: The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences. This retrospective cohort will be the backbone of future translational studies aimed at identifying new molecular, histological, circulating and radiological tumor biomarkers, potentially useful at every stage of diagnosis and prognostic or theranostic evaluation.

Detailed description: The aim is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences.

Eligibility criteria: Inclusion Criteria:

* 18 years of age or older,
* with histologically proven hepato-cholangiocarcinoma, fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma or hepatic angiosarcoma
* diagnosed after January 01, 2018 living or deceased at the time of registration in the cohort
* for living patients who have not objected to the research: (note of non-objection to be attached° agreeing to participate in ancillary studies must sign the biological consent form for participation in biological studies.

Exclusion Criteria:

* without social security
* No access to tumor block

Primary outcomes:
measure: Description of the clinical, histological and radiological characteristics of various rare primary liver cancers
timeFrame: up to 5 years from the date of diagnosis
Secondary outcomes:
measure: Recurrence-free survival (for non-metastatic patients)
timeFrame: up to 5 years from diagnosis
measure: Progression-free survival (for metastatic patients)
timeFrame: up to 5 years from diagnosis
measure: Overall survival
timeFrame: up to 5 years from diagnosis
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU Amiens picardie
city: Angers
country: France
facility: Chu Angers
city: Beauvais
country: France
facility: Ch - Centresimone Veil de Beauvais
city: Besançon
country: France
facility: Chu Jean Minjoz
city: Bethune
country: France
facility: Ch Bethune Beuvry
city: Bobigny
country: France
facility: Avicenne
city: Caen
country: France
facility: Cote de Nacre
city: Clichy
country: France
facility: Chu de Clichy Hopital Beaujon
city: Creteil
country: France
facility: Centre Hospitalier Universitaire Henri Mondor
city: Dijon
country: France
facility: CHU
city: La Tronche
country: France
facility: Chu Grenobles Alpes
city: Lille
country: France
facility: Centre Hospital Universitaire de lille
city: Longjumeau
country: France
facility: Longjumeau Ch
city: Lyon
country: France
facility: Ch Edouard Herriot
city: Lyon
country: France
facility: Centre Léon Berard
city: Lyon
country: France
facility: Clinique de La Sauvegarde
city: Lyon
country: France
facility: La Clinique de La Sauvegarde
city: Lyon
country: France
facility: Chu Edouard Herriot
city: Lyon
country: France
facility: Chu La Croix Rousse
city: Lyon
country: France
facility: Lyon Cac Leon Berard
city: Lyon
country: France
facility: Lyon La Croix Rousse
city: Marseille
country: France
facility: Hopital Saint Joseph
city: Marseille
country: France
facility: Chu de La Timone
city: Metz
country: France
facility: CHR - Metz Thionville Hopital de Mercy
city: Paris
country: France
facility: Chu de Paris Saint Antoine
city: Paris
country: France
facility: AP - HP - Pitié Salpêtrière
city: Pau
country: France
facility: PAU CH
city: Perpignan
country: France
facility: Centre Hospitalier de Perpignan
city: Pessac
country: France
facility: Hopital Haut Leveque
city: Poitiers
country: France
facility: Chu de Poitiers
city: Pringy
country: France
facility: CH - Annecy Genevois
city: Reims
country: France
facility: Chu Robert Debre
city: Rennes
country: France
facility: CAC - Eugène Marquis
city: Saint-Herblain
country: France
facility: Ico Site Rene Gauducheau
city: Saint-Malo
country: France
facility: Groupe Hospitalier Rance Emeraude
city: Saint-Priest-en-Jarez
country: France
facility: Hopital Nord Chu Saint Etienne
city: Toulouse
country: France
facility: Chu Rangueil
city: Tours
country: France
facility: Chru de Tours
city: Villejuif
country: France
facility: Chu Paul Brousse
city: Villejuif
country: France
facility: Gustave Roussy
Study officials:
affiliation: Federation Francophone de Cancerologie Digestive
name: jean-charles nault, Pr
role: PRINCIPAL_INVESTIGATOR
References: